1036761-99-5

Basic information

• Product Name: 4-broMo-2-(tetrahydro-2H-pyran-4-yloxy)pyridine
• Synonyms: 4-broMo-2-(tetrahydro-2H-pyran-4-yloxy)pyridine
• CAS NO: 1036761-99-5
• Molecular Formula: C10H12BrNO2
• Molecular Weight: 258.11178
• Mol File: 1036761-99-5.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-broMo-2-(tetrahydro-2H-pyran-4-yloxy)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-broMo-2-(tetrahydro-2H-pyran-4-yloxy)pyridine(1036761-99-5)
• EPA Substance Registry System: 4-broMo-2-(tetrahydro-2H-pyran-4-yloxy)pyridine(1036761-99-5)

Safety Data

• Hazardous Substances Data: 1036761-99-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
4-bromo-2-(tetrahydro-2H-pyran-4-yloxy)pyridine is used as a building block for the synthesis of pharmaceutical compounds, contributing to the development of new medications.
Used in Organic Chemistry:
In the field of organic chemistry, 4-bromo-2-(tetrahydro-2H-pyran-4-yloxy)pyridine may be employed in various chemical reactions and processes, potentially leading to the creation of novel organic compounds.
Used in Material Science:
4-bromo-2-(tetrahydro-2H-pyran-4-yloxy)pyridine could be utilized in material science for the development of new materials with specific properties, given its unique chemical structure and potential for interaction with other compounds.

Upstream product

• 25637-16-5 4-bromotetrahydro-2H-pyran 
• 2081-44-9 Tetrahydro-pyran-4-ol 
• 73583-37-6 2-chloro-4-bromopyridine 

Relevant articles and documents

TARGETED BIFUNCTIONAL DEGRADERS

The present invention provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of certain circulating proteins. In another aspect, the present invention provides bifunctional compounds that can be used to promote or enhance degradation of certain autoantibodies. In certain embodiments, treatment or management of a disease and/or disorder requires degradation, removal, or reduction in concentration of the circulating protein or the autoantibody in the subject. Thus, in certain embodiments, administration of a compound of the invention to the subject removes or reduces the circulation concentration of the circulating protein or the autoantibody, thus treating, ameliorating, or preventing the disease and/or disorder. In certain embodiments, the circulating protein is TNF.

TRICYCLIC MODULATORS OF TNF SIGNALING

The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, prodrugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.

NEW COMPOUNDS

The invention relates to new bicyclic heterocyclic derivative compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.